entinostat has been researched along with B16 Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nguyen, A | 1 |
| Ho, L | 1 |
| Workenhe, ST | 1 |
| Chen, L | 1 |
| Samson, J | 1 |
| Walsh, SR | 1 |
| Pol, J | 1 |
| Bramson, JL | 1 |
| Wan, Y | 1 |
| Kato, Y | 1 |
| Yoshino, I | 1 |
| Egusa, C | 1 |
| Maeda, T | 1 |
| Pili, R | 1 |
| Tsuboi, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for entinostat and B16 Melanoma
| Article | Year |
|---|---|
HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; CD8-Positive T-Lymphocytes; Cell Pol | 2018 |
Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides | 2014 |